NASDAQ · Health care

Ensysce Biosciences, Inc. (ENSC)

Ensysce Biosciences, Inc. brought in $4.5M of revenue over the twelve months to June 30, 2026, down 39.3% from a year earlier. It posted a net loss of $12.6M. In fiscal 2025 capital spending exceeded operating cash flow by $7.9M. At June 30, 2026 it held $676.7K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

Watch ENSC in 60 seconds

Price

$0.41

+3.05% on the day · September 25, 2026

52-week range $0.23 to $2.75

Market cap

$8M

Revenue (last 12 months)

$4.5M

-39.3% year on year

Net margin

-280.5%

What Ensysce Biosciences, Inc. does

Ensysce Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ENSC.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$5.1M	-$10.2M	-$10.2M	-$3.98	-$7.9M
2024	$5.2M	-$6.7M	-$8M	-$11.45	n/a
2023	$2.2M	-$10.7M	-$10.6M	-$70.40	n/a
2022	$2.5M	-$24.2M	-$25.1M	-$2,092.79	n/a
2021	$3.5M	-$19.9M	-$29.9M	-$22.22	n/a
2020	$3.9M	-$1.6M	$4.3M	$0.00	n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around November 13, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 14, 2025. Not a date the company has announced. See the report calendar

Where ENSC ranks in Health care

Revenue$5.1M

#507 of 646 in Health care · Bottom 22%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Ensysce Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 25, 2026
Other event 8-K
August 24, 2026
Other event 8-K
August 18, 2026
Activist stake changed SCHEDULE 13D/A
August 13, 2026
Quarterly report 10-Q · period to June 30, 2026Revenue fell 15% to $1.2M versus the same quarter last year; diluted EPS -$0.20 versus -$0.79.
August 13, 2026
Quarterly results 8-K
August 6, 2026
Exhibits 8-K/A
August 6, 2026
Acquisition or sale completed 8-K
July 15, 2026
Executive or director change 8-K
June 4, 2026
Shelf registration to sell securities S-3
May 22, 2026
Stock exchange listing notice 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 18, 2026. Insider transactions on SEC

Insider trades

What the people running Ensysce Biosciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders bought $198K worth of shares on the open market in the last 90 days and sold none.

Bought (open market)

$198K

last 90 days

Sold

last 90 days

Net bought

400,000

$198K

Date	Insider	What	Shares	Price	Value	Filing
August 7, 2026	Gower Bob GDirector	Bought	400,000	$0.50	$198K	Form 4
April 23, 2026	Gower Bob GDirector	Bought	508,614	$0.48	$246.2K	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns ENSC

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
Bob Gene Gower13D, may seek influence	6.1%	1,206,576	August 18, 2026

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

1 insiders reported holding 916,740 shares in total, about $378K at the last price.

Holder	Shares	As of
Gower Bob GDirector	916,740	August 7, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about ENSC

What does Ensysce Biosciences, Inc. do?

Ensysce Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ENSC.

Is Ensysce Biosciences, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $12.6M on revenue of $4.5M.

How much revenue does Ensysce Biosciences, Inc. make?

Over the twelve months to June 30, 2026 Ensysce Biosciences, Inc. reported revenue of $4.5M. That is 39.3% less than a year earlier.

When did Ensysce Biosciences, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from August 25, 2026.

Similar companies

Compare ENSC with

Compare ENSC with any company

Follow ENSC

Get an email when Ensysce Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow ENSC: get an email when it files

Where the numbers come from

Financial figures are the values Ensysce Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.